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Abstract 
Objective: This study was conducted to identify the risk factors for intrauterine device failure. 
Materials and methods: A retrospective case-control study was carried out between 1999 and 
2002. Cases (women with an IUD and a confirmed pregnancy) and controls (women with an 
IUD who were not pregnant) were recruited by gynaecologists. An anonymous questionnaire 
was filled in during the consultation, with specific items regarding any type of drugs used before 
the predicted fertile period for cases and within the cycle which ended in menses for controls. 
Results: Two hundred and sixteen cases were compared with 657 controls. Age was associated 
with intrauterine device failure, with a significantly lower failure risk in women older than 35 
years. A significant relationship was observed between a history of IUD expulsion and IUD 
failure risk (age-adjusted odds ratio 3.31, 95% CI: 1.40-7.81). No relationship was observed 
between risk of IUD failure and gynaecological background (fibroma, polyps, miscarriage), nor 
with any type of medicine taken by the woman. 
Conclusion: This study is clearly reassuring as we found that anti-inflammatory drugs and any 
other medicines taken by the woman were not implicated in IUD failure. Only a history of 
previous IUD expulsion was found to be a risk factor for failure, indicating that these women 
should have regular medical and echographical follow-up. 
Comparing the efficacy rate of various types of IUD, we found a clear advantage for 
levonorgestrel-releasing devices. 
 
 
Keywords: intrauterine device, intrauterine failure, risk factors, reproductive health, family 
planning 
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Introduction 
Worldwide, the intrauterine device (IUD) is one of the most frequently used contraceptive 
methods, and the pregnancy rate of IUD users is estimated at between 1 and 3 per 100 woman-
years (WHO, 1990; Mishell, 1998; FFPRHC, 2004a). Although the effectiveness of IUDs is 
excellent, such failure rates will lead to a substantial number of unwanted pregnancies and 
subsequent induced abortions. Unfortunately, very few studies have tried to identify the risk 
factors for IUD failure (Sivin and Schmidt, 1987). In a recent review, several factors (size and 
shape of the device, technical skills of the healthcare staff, uterine position and length of the 
endometrium) were analysed but showed no significant relationship with IUD failure. Only the 
copper content of the device (with a significant link between lowest failure rates and largest 
copper surface areas) and the age of the woman (reduction of failure rate with increasing 
female age) were identified as IUD failure risk factors (Thonneau et al., 2001). In a case-
control study performed in 2003 in Spain (71 cases and 284 controls), the relation between 
pregnancy in copper-IUD users, uterine position and hysterometry was analysed. Neither of 
these two gynaecological characteristics was associated with an increased risk of pregnancy 
(Avecilla-Palau and Moreno, 2003). 
More than 15 years ago, a case-control study conducted in France suggested that aspirin use 
could be a significant risk factor for IUD failure (OR:1.23;1.04-1.46) (Papiernik et al., 1989). 
Nevertheless, several limitations (absence of a statistically significant relationship with the use 
of other non-steroidal anti-inflammatory drugs or with steroids) and the low odds ratio 
observed largely contributed to weaken the authors’ hypothesis, which has not as yet been 
confirmed by other studies. 
In order to identify IUD failure risk factors in intrauterine pregnancy, we performed a large 
case-control study. 
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Materials and methods 
The retrospective case-control study was carried out in France between 1999 and 2002, in close 
collaboration with the French federation of medical gynaecology and all regional boards of this 
federation. General information, including the aim and the practical considerations of the 
study, was delivered by mail and at local meetings to all health professionals involved in 
family planning. The study was approved by a national ethics board. 
 
Cases and controls were directly recruited by gynaecologists during their own practice. Cases 
were defined as confirmed pregnancy of less than 4 months duration (positive pregnancy test 
and/or positive echography) occurring in a woman with an IUD inserted for more than six 
months, and aged between 18 and 44 years. Controls were the next three following women 
with an IUD inserted for more than six months, who were not pregnant (last menses within the 
ten days prior to the consultation) and were aged between 18 and 44 years. 
 
An anonymous questionnaire was administered by the gynaecologist to both cases and 
controls, and filled in during the consultation. Before the interview, informed consent was 
given and signed by each volunteer. The items included in the questionnaire were female age, 
parity and principal reproductive history, type of IUD, number of sexual partners or a new 
sexual partner (in the last six months), trade name of the IUD. A specific section was also 
devoted to the medications used by the woman. For cases, we asked about any type of 
treatment (oral, cutaneous or by injection) taken in the period including the last menses and the 
following 10 days (i.e. including the predicted fertile period). For controls, we asked women 
for the same type of information on drugs used during their last cycle (i.e. the cycle which 
ended in menses). For both cases and controls, if drugs had been used their exact trade name 
were recorded. 
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Information collected by gynaecologists was then coded by the research team. Firstly, IUDs 
were classified by type: levonorgestrel-releasing (LNG-IUD: Mirena®, Schering SA), IUD 
with copper area between 375 and 380 mm2 (Gyne T380®, Laboratoire CCD; MLCu375®, 
Organon; Gynelle 375®, Laboratoire CCD), Cu-IUD with silver core and copper area of 200 
mm2 (Nova T®, Schering SA), Cu-IUD with copper area of 300 mm2 (Sertalia®, Theramex), 
and anchored IUD (GyneFix®, Golaz SA). 
Secondly, the trade names of drugs taken by the woman were pooled by drug type: steroids and 
non-steroidal anti-inflammatory agents, antibiotics, analgesics, vaginal antiseptics and anti-
depressants. Furthermore, it was determined precisely if the drugs were taken in the ‘exposed 
period’, i.e. the last cycle and the following 10 days before the predicted fertile period for 
cases, and the last cycle for controls. 
 
 
Statistical analysis 
Data were analysed by SAS and Stata software (8.0 versions). The chi-square test was used for 
comparing percentages. Crude and adjusted odds ratios and 95% confidence intervals were 
estimated by logistic regression. Sample size, stratifications, adjustments, and other 
epidemiological analysis were performed according to Schlesselman’s recommendations 
(Schlesselman, 1982). The sample size was calculated to detect a two-fold increase in risk of 
pregnancy with IUD with a frequency of 5% in controls for alpha = 0.05 and 1-beta=0.80. 
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Results 
During the study period, 1,001 women were enrolled. We excluded 102 women aged 45 years 
and over. Furthermore, 26 questionnaires were excluded due to lack of key information (age, 
localisation of the pregnancy for cases). Finally, 216 cases were compared with 657 controls. 
Table 1 shows sociodemographic and clinical characteristics of cases and controls. The mean 
age of cases, 34.3 years (SD = 4.4), was significantly lower than that of controls, 37.0 years 
(SD = 5.2) (p<0.001). Age was associated with intrauterine device failure, with a significantly 
lower failure risk in women older than 35 years compared with those less than 30-34 years old: 
OR = 0.49 (95% CI: 0.34-0.71) for age 35-39 years, and OR = 0.14 (95% CI: 0.08-0.23) for 
age 40-44 years. 
No significant differences were observed regarding parity and IUD failure risk, but the number 
of enrolled women not having given birth was low (n = 28). Educational level, living with male 
partner, size of town of residence, and current IUD past expiry date were not found to be 
significant IUD failure risk factors. 
 
Table 2 illustrates the distribution of main gynaecological disorders between cases and 
controls. We observed a significant relationship between a history of IUD expulsion and IUD 
failure risk (age-adjusted odds ratio 3.31, 95% CI: 1.40-7.81). Similarly, a history of breast 
disorders was significantly associated with a lower failure risk (p=0.02), but this relationship 
was linked to female age effect (no statistical difference was observed after age adjustment). 
None of the other variables regarding history of gynaecological disorders were found to be 
significant risk factors for IUD failure, even after age adjustment. 
 
In this study, 307 women, 82 cases and 225 controls, stated that they had taken medicines 
within two weeks before conception for cases or in the first part of the last menstrual cycle for 
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controls. For each case and control, we checked the medicines used and then classified them in 
types, as anti-inflammatory agents, analgesics, antidepressants, antibiotics, etc.. For drugs 
classified as anti-inflammatory agents, we analysed steroids and non-steroids separately. 
Finally and as shown in Table 3, none of the medicines taken, of whatever type, were found to 
be significant risk factors for IUD failure. 
 
We analysed risk of pregnancy according to type of intrauterine device Comparing efficacy 
between several types of IUD, we found that a levonorgestrel-releasing device (Mirena®) was 
the most effective. In a regression analysis model (age-adjusted) and taking levonorgestrel-
releasing IUDs as the reference group, we found that pregnancy risk was multiplied by 2.70 
(95% CI: 1.11-6.56) for IUDs with a copper surface of 375 mm2 (Gyne-T380®, MLCu375®, 
Gynelle375), by 7.20 (95% CI: 3.01-17.22) for IUDs with a copper surface of 200 mm2 and a 
silver core (Nova T®), by 8.45 (95% CI, 3.19-22.39) for copper-bearing IUDs with a total 
copper area of 300 mm2 (Sertalia®), and by 24.43 (95% CI, 4.73-126.20) for women with the 
GyneFix® device (however, the number of subjects with this type of IUD was relatively low; n 
= 9) (Table 4). 
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Discussion 
Like previous published studies in this domain (Sivin and Schmidt, 1987; Thonneau et al., 
2001), we observed that IUD efficacy is affected by age. In our case-control study, risk of IUD 
failure was lower in older women, which is due to decreasing fertility with advancing age. 
We also observed that a history of IUD expulsion was a significant risk factor for failure of the 
device (age-adjusted odds ratio 3.31, 95% CI: 1.40-7.81). This item ‘history of IUD expulsion’ 
is not mentioned as a significant failure risk factor in the literature. Nevertheless, the 
consequences of a disproportion between IUD size and the uterine cavity have been analysed 
by several authors (Anteby et al., 1993; Castro et al., 1993). Hasson et al. observed that the 
length of the endometrial uterine cavity length conditions the effectiveness of IUDs, recording 
higher rates of pregnancies and expulsion in women where endometrial uterine cavity length 
was not in adequation with the size of the IUD (Hasson et al., 1976). Furthermore, the 
intrauterine position of the device, which is closely linked to its contraceptive effectiveness, 
has been recently assessed in a prospective study of 195 women, where the prevalence of 
abnormally positioned IUD was as high as 4%, 6 weeks after insertion (de Kroon et al., 2003). 
We may therefore hypothesize that women with a history of IUD expulsion are likely to have 
potential unfavourable uterine conditions (small uterine size, slight malformation or 
malposition), resulting in subsequent devices also being in an abnormal position and so leading 
to significantly decreased efficacy. 
Given that a history of IUD expulsion has to be considered as a risk factor for IUD failure, 
clinicians involved in family planning must be aware of this information, so that these women 
may have regular echographical surveillance. 
We observed no significant relationship between IUD failure and history of polyps, fibroma, 
miscarriage or previous pregnancy with IUD (cf. Table 2). These gynaecological backgrounds 
should not be considered as a formal contraindication for IUD insertion. 
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In our case-control study, we observed no relationship between use of anti-inflammatory drugs 
and intrauterine device failure. No significant relationship was observed between any type of 
medicine taken by the woman and risk of IUD failure. In 1989, French authors found that use 
of aspirin tablets significantly increased the risk of IUD failure (Papiernik et al., 1989). 
Nevertheless, their conclusions should certainly be treated with caution due to several 
limitations. Firstly, in this study medicine use differed significantly between cases (47%) and 
controls (41%), whereas in our study this variable did not significantly differ between the two 
groups (p=0.64). Secondly, the difference observed by the above authors in aspirin tablet use 
was not found with other anti-inflammatory drugs, which is somewhat surprising (in our study, 
regarding absence of effect of drugs on IUD failure, all drugs had results in the same range). 
Finally, the very low odds ratio (1.23; 95% CI 1.04-1.46) found by the authors for aspirin 
tablet use could well be due to a recall bias rather than to a true IUD failure risk effect. 
 
Another interesting finding of this study is that efficacy differed according to the type of IUD. 
As shown in Table 4, levonorgestrel-releasing IUDs were the most effective, which is in 
agreement with several recent publications (Pakarinen et al., 2003; French et al., 2000; 
FFPRHC, 2004b). Furthermore, comparison of different types of copper IUDs showed that 
those with a surface area of less than 300 mm2 were significantly less effective, which is also 
in accordance with the literature (Batar et al., 2002; Cao et al., 2004; Cox et al., 2002). Risk of 
pregnancy is known to be higher in women with GyneFix devices (Dennis et al., 2001; 
Wildemeersch et al., 2003) but we had relatively few women using this type of IUD (n=9). 
Regarding ‘history of previous IUD expulsion’, the odds ratios were not more significant for 
LNG-IUDs although the confidence interval was very large (9.3; CI:0.6-134.3), but remained 
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significant for IUDs with a copper area between 375 and 380 mm2 (for other types, the number 
of cases was too small). 
 
Limitations 
Due to the retrospective design, recall bias could be an important factor if cases were more 
likely than controls to remember potential risk factors (medicines taken, for example). In fact, 
we believe that women are not aware of the potential impact of drugs on IUD effectiveness. 
Moreover, the proportion of women who had taken any medicines during the study period was 
very similar, 39% in the case group versus 37% in the control group (p=0.64). Because of this, 
we may assume that recall bias did not play an important part in our study. 
Practitioners taking part in this study did so on a voluntary basis. Although this large 
multicentre trial involved more than one hundred practitioners, extrapolation of the results to 
other populations must be done with caution. 
 
Conclusion 
Although intrauterine devices are one of the most effective methods of contraception, failures 
still represent a substantial number of unintended pregnancies. The results of this study are 
clearly reassuring as we found that anti-inflammatory drugs or any other medicines taken by 
the woman did not affect IUD efficacy. 
In our case-control study, a history of previous IUD expulsion was found to be a risk factor for 
IUD failure. Nevertheless, a previous expulsion is not a contraindication for a new IUD, on 
condition that these women have regular medical and echographical follow-up. Finally, 
comparison of the efficacy rate between various types of IUD showed a clear advantage for 
levonorgestrel-releasing IUDs, and among Cu-IUDs, for those with the largest total copper 
area. 
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Table 1. Sociodemographic and clinical characteristics of cases and controls 
 Cases Controls Crude OR 
 n (%) n (%) (95% CI)  
 
Age (years) 
18-24 5 (2.3) 15 (2.3) 0.50 (0.17-1.42) 
25-29 28 (13.0) 62 (9.4) 0.67 (0.40-1.13) 
30-34 88 (40.7) 131 (19.9) 1 (ref. group) 
35-39 75 (34.7) 228 (34.7) 0.49 (0.34-0.71) 
40-44 20 (9.3) 221 (33.6) 0.14 (0.08-0.23) 
 
Living with male partner 
No 6 (2.8) 47 (7.1) 1 
Yes 209 (97.2) 610 (92.9) 2.68 (1.13-6.37) 
 
Educational level 
Low 124 (58.5) 410 (62.6) 0.84 (0.61-1.15) 
High 88 (41.5) 245 (37.4) 1 
 
Size of town of residence 
< 20,000 inhabitants 121 (56.8) 379 (58.8) 0.92 (0.67-1.26) 
> 20,000 inhabitants 92 (43.2) 265 (41.2) 1 
 
Parity 
0 5 (2.4) 23 (3.5) 0.66 (0.25-1.76) 
1 42 (19.7) 129 (19.7) 0.99 (0.67-1.46) 
 2 166 (77.9) 503 (76.8) 1 
 
Current IUD past expiry date 
 
No 191 (96.9) 616 (97.5) 1 
Yes 6 (3.1) 16 (2.5) 1.209 (0.47-3.134) 
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Table 2. Gynaecological background in cases and controls 
 Cases Controls Crude OR Age-adjusted 
 yes/no (%) yes/no (%) (95% CI) OR (95% CI) 
History   
uterine-vaginal infection 24/191 (12.5) 93/561 (16.6) 0.76 (0.47-1.22) 
polyps 2/213 (0.9) 8/645 (1.2) 0.76 (0.16-3.59) 
fibroma 5/210 (2.4) 22/630 (3.5) 0.68 (0.26-1.82) 
breast disorders 8/207 (3.9) 57/596 (9.6) 0.40 (0.19-0.86) 0.55 (0.25-1.21) 
ectopic pregnancy 1/212 (0.5) 11/644 (1.7) 0.28 (0.04-2.15) 
miscarriage 40/173 (23.1) 115/540 (21.3) 1.09 (0.73-1.62) 
induced abortion 40/173 (23.1) 169/485 (34.8) 0.66 (0.45-0.98) 0.74 (0.49-1.10) 
previous pregnancy with IUD  9/180 (5.0) 29/583 (4.5) 1.00 (0.47-2.16) 
IUD expulsion 12/173 (6.9) 14/596 (2.3) 2.95 (1.34-6.50) 3.31 (1.40-7.81) 
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Table 3. Medicines taken by women before conception (cases) or in the first part of the last 
menstrual cycle (controls) 
 Cases Controls Crude OR 
 yes/no (%) yes/no (%) (95% CI) 
 
Any type of medicine 82/127 (64.6) 225/376 (59.8) 1.08 (0.78-1.49) 
 
Analgesics 18/188 (9.6) 54/544 (9.9) 0.97 (0.55-1.69) 
Antibiotics 4/202 (2.0) 10/588 (1.7) 1.16 (0.36-3.75) 
Antidepressants 12/194 (6.2) 23/575 (4.0) 1.54 (0.76-3.17) 
 
Anti-inflammatory agents 24/184 (13.0) 60/540 (11.1) 1.17 (0.71-1.94) 
 - steroids  8/199 (4.0)  12/588 (2.0) 1.97 (0.79-4.89) 
 - non-steroidal 16/191 (8.4)  50/550 (9.1) 0.92 (0.51-1.66) 
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Table 4. Efficacy rate according to IUD type (multivariate analysis) 
 Cases Controls  Crude OR Age-adjusted OR 
   (95% CI) (95% CI) 
 
Levonorgestrel-releasing hormone (Mirena) * 6  87 1 (ref. group) 1 (ref. group) 
Cu-IUD copper area 375-380 mm² ** 55  293 2.72 (1.13-6.54) 2.70 (1.11-6.56) 
Cu-IUD copper area 300 mm² *** 29  40 10.51 (4.04-27.33) 8.45 (3.19-22.39) 
Cu-IUD copper area 200 mm² **** 108  218 7.18 (3.04-16.96) 7.20 (3.01-17.22) 
GyneFix 5  4 18.12 (3.83-85.68) 24.43 (4.73-126.20) 
* Levonorgestrel-releasing IUD (52 mg): Mirena® 
** Copper-bearing IUD, total copper area 375-380 mm2: Gyne T380®, MLCu375®, Gynelle 375® 
*** Copper-bearing IUD, total copper area 300 mm²: Sertalia® 
**** Copper-bearing IUD with a silver core, total copper area 200 mm2: NovaT® 
 
 
